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COVID-19 drug practices risk antimicrobial resistance evolution 
Antimicrobial resistance is one of the biggest 
challenges facing modern medicine. Because the 
management of COVID-19 is increasingly becoming 
dependent on pharmacological interventions, there 
is greater risk for accelerating the evolution and 
spread of antimicrobial resistance. A study in a tertiary 
hospital environment revealed concerning colonisation 
patterns of microbes during extended periods.1 It also 
highlighted the diversity of antimicrobial resistance 
gene reservoirs in hospitals that could facilitate 
the emergence and transmission of new modes of 
antibiotic resistance.
Admission and release of patients from tertiary 
hospitals have risen dramatically in the past year due 
to the COVID-19 pandemic, with many hospitals 
expanding beyond capacity. With hospitalisations 
exceeding normal capacity due to COVID-19 combined 
with impaired immune function in patients, risks 
of co-infections have substantially increased.2,3 
The gap in a comprehensive understanding of co-
infection and comorbidity caused by COVID-19 
has led to rapidly changing protocols for patient 
handling, including administering multiple drugs 
around the world (figure).4 The use of antiparasite, 
antiviral, antibacterial, and anti-inflammatory drugs 
for preventing secondary infections in patients with 
COVID-19 during a prolonged pandemic will inevitably 
invite future complications, including aggravation of 
antimicrobial resistance. This is particularly relevant 
in light of the successive emergence of mutations 
that increase SARS-CoV-2 fitness, which could be 
responsible for recurrent COVID-19 waves.5 Of note, 
because most of these drugs are used for other target 
pathogens, we might not only increase resistance in 
COVID-19 but also face challenges in the treatment of 
other bacterial and viral infections.
With drugs frequently replaced by new therapeutic 
options (figure), the fear of increased antimicrobial 
resistance evolution and spread are a reality. There was 
an increasing demand for and misuse of various drugs 
in the treatment of COVID-19 irrespective of paucity 
of scientific evidence.6 This has even been exacerbated 
by rapid publication of some papers without extensive 
peer-review and their recommendations by WHO and 
the centres for disease control and prevention across 
the world without evaluations.4 Social media has also 
played an alarming role in increasing the popularity 
(both negative and positive) of some drugs, including 
a number of pharmacological substances with no 
proven effects.7 As an additional threat, imperfect 
drug penetration to patients with COVID-19 might 
lead to rapid evolution of multidrug resistance.8 This 
might be worsened by alterations observed in the gut 
microbiota of patients hospitalised with COVID-19, 
which represents a propitious dysbiotic environment 
for the emergence and dissemination of multidrug 
resistance.9
Nosocomial transmission of SARS-CoV-2 from 
patients to health-care workers was reported at 
the Wuhan Union Hospital, Wuhan, China, as early 
as Jan 16, 2020.10 However, investigations on 
accompanying multidrug-resistant infections have 
not been done in these and other studies. This is 
of note because there is substantial push towards 
administration of convalescent plasma therapy as a 
COVID-19 treatment option on the basis of success 
reported during previous global outbreaks, such as 
severe acute respiratory syndrome, Middle East respiratory 
syndrome, and H1N1 Influenza.11
We must be vigilant and cautious that the fight 
against COVID-19 does not invite another significant 
threat to humankind.
Figure: Use of multiple COVID-19 drugs in practice
Timeline of first appearance of major antiparasite, antiviral, antibacterial, and anti-inflammatory drugs 
for the treatment of COVID-19 in preprints, in a peer-reviewed article, as a Google search trend, as a worldwide 
Twitter trend, and the first time mentioned by WHO in situation reports. The other essential drugs for 
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